Lohmann, Ana Elisa
,
Liebman, Mira F.
Brien, William
Parulekar, Wendy R.
Gelmon, Karen A.
Shepherd, Lois E.
Ligibel, Jennifer A.
Hershman, Dawn L.
Rastogi, Priya
Mayer, Ingrid A.
Hobday, Timothy J.
Lemieux, Julie
Thompson, Alastair Mark
Pritchard, Kathleen I.
Whelan, Timothy Joseph
Mukherjee, Som D.
Chalchal, Haji I.
Bernstein, Vanessa
Stambolic, Vuk
Chen, Bingshu E.
Goodwin, Pamela Jean
Funding for this research was provided by:
Hold’Em for Life Translating Discoveries into Breast Cancer cures
Canadian Cancer Society Research Institute (CCSRI grant (#021039))
National Institutes of Health (#CA180863)
Canadian Breast Cancer Foundation
Breast Cancer Research Foundation
Apotex
Article History
Received: 18 April 2017
Accepted: 19 April 2017
First Online: 26 April 2017
Compliance with ethical standards
:
: Drs. Lohmann, Liebman, Brien, Parulekar, Gelmon, Shepherd, Ligibel, Hershman, Rastogi, Hobday, Lemieux, Thompson, Whelan, Mukherjee, Chalchal, Stambolic, Chen, and Goodwin declare no conflict of interest.Dr. Pritchard reported receiving consulting fees from AstraZeneca, Pfizer, Roche, Amgen, Novartis, GlaxoSmithKline, and Eisai. Dr. Mayer received consulting fees from Novartis and Pfizer. Dr. Bernstein received consulting fees from Bristol-Myers Squibb.
: All procedures performed in the study were in accordance with the ethical standards of the institutional review board of the participating institutions and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: All patients provided written informed consent to participate, including conduct of the correlative analyses reported here.